Zobrazeno 1 - 10
of 233
pro vyhledávání: '"J. P. H. Drenth"'
Autor:
S. E. Aapkes, L. H. P. Bernts, A. P. van den Berg, M. van den Berg, H. Blokzijl, A. E. P. Cantineau, M. D. A. van Gastel, R. J. de Haas, P. Kappert, R. U. Müller, F. Nevens, R. Torra, A. Visser, J. P. H. Drenth, R. T. Gansevoort
Publikováno v:
BMC Gastroenterology, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background In patients with severe polycystic liver disease (PLD), there is a need for new treatments. Estrogens and possibly other female sex hormones stimulate growth in PLD. In some patients, liver volume decreases after menopause. Female
Externí odkaz:
https://doaj.org/article/249419e1e30e46f0b6d00e3d79909557
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 164
The liver has a major role in the pharmacokinetics and pharmacodynamics of medicines and hepatic impairment could therefore lead to increased plasma levels and adverse drug reactions. Due to the large overcapacity of the liver, medication adjustments
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ff5c98e33c3aeae27bd402a69ec8dafa
https://pubmed.ncbi.nlm.nih.gov/33201633
https://pubmed.ncbi.nlm.nih.gov/33201633
Autor:
M A, Lantinga, R G L, de Sévaux, T J G, Gevers, W J G, Oyen, J W, de Fijter, D, Soonawala, R, Zietse, M, Salih, N F, Casteleijn, E M, Spithoven, E, Meijer, R T, Gansevoort, J P H, Drenth On Behalf Of The Dipak Consortium
Publikováno v:
The Netherlands Journal of Medicine. 76(5):226-234
BACKGROUND: Cyst infection may occur in autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD). Antimicrobial agents often fail to control infection, leading to invasive action. We aimed to identi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::95b3bedaf4f2a97b9b059c9e81b72ec5
https://hdl.handle.net/11370/bc360867-bdb4-4b82-9f52-c49ea5d76ff4
https://hdl.handle.net/11370/bc360867-bdb4-4b82-9f52-c49ea5d76ff4
Autor:
R. Liberal, Y. S. de Boer, R. J. Andrade, G. Bouma, G. N. Dalekos, A. Floreani, D. Gleeson, G. M. Hirschfield, P. Invernizzi, M. Lenzi, A. W. Lohse, G. Macedo, P. Milkiewicz, B. Terziroli, B. van Hoek, J. M. Vierling, M. A. Heneghan, on behalf of the International Autoimmune Hepatitis Group (IAIHG), A. Pares, A. J. Montano-Loza, A. Granito, A. E. Kremer, C. Schramm, C. Lammert, E. L. R. Cancado, E. Bjornsson, F. Lammert, G. M. Hirschflield, H. Hofer, I. Mackay, J. Neuberger, J. P. H. Drenth, C. M. J. van Nieuwkerk, L. Muratori, M. Swain, M. Heneghan, M. Zeniya, O. Chazouilleres, P. Gines, R. Chapman, T. Berg, H. van Buuren, X. Ma
Publikováno v:
Liberal, R, de Boer, Y S, Andrade, R J, Bouma, G, Dalekos, G N, Floreani, A, Gleeson, D, Hirschfield, G M, Invernizzi, P, Lenzi, M, Lohse, A W, Macedo, G, Milkiewicz, P, Terziroli, B, van Hoek, B, Vierling, J M, Heneghan, M, Pares, A, Montano-Loza, A J, Granito, A, Kremer, A E, Floreani, A, Lohse, A W, van Hoek, B, Terziroli, B, Schramm, C, Lammert, C, Cancado, E L R, Bjornsson, E, Lammert, F, Dalekos, G N, Bouma, G, Hirschflield, G M, Macedo, G, Hofer, H, Mackay, I, Neuberger, J, Vierling, J M, Drenth, J P H, van Nieuwkerk, C M J, Muratori, L, Lenzi, M, Swain, M, Heneghan, M, Zeniya, M, Chazouilleres, O, Gines, P, Milkiewicz, P, Andrade, R J, Ma, X & the International Autoimmune Hepatitis Group (IAIHG) 2017, ' Expert clinical management of autoimmune hepatitis in the real world ', Alimentary Pharmacology and Therapeutics, vol. 45, no. 5, pp. 723-732 . https://doi.org/10.1111/apt.13907
Alimentary Pharmacology and Therapeutics, 45(5), 723-732
Alimentary Pharmacology & Therapeutics, 45, 723-732
Alimentary Pharmacology & Therapeutics, 45, 5, pp. 723-732
Alimentary Pharmacology and Therapeutics, 45(5), 723-732
Alimentary Pharmacology & Therapeutics, 45, 723-732
Alimentary Pharmacology & Therapeutics, 45, 5, pp. 723-732
none 55 si First published: 22 December 2016 Background: High-quality data on the management of autoimmune hepatitis (AIH) are scarce. Despite published guidelines, management of AIH is still expert based rather than evidence based. Aim: To survey ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d91175f447c75f0806a630fa90b826e1
https://hdl.handle.net/2066/169664
https://hdl.handle.net/2066/169664
Autor:
M, van Dijk, P A M, Kracht, J E, Arends, H, Blokzijl, D M, Burger, K J, van Erpecum, B, van Hoek, R J, de Knegt, D, Posthouwer, D, Ramsoekh, B J A, Rijnders, J, Schinkel, S B, Willemse, M, van der Valk, J P H, Drenth, On, Behalf Of The HepNed Study Group
Publikováno v:
The Netherlands journal of medicine. 77(4)
Chronic hepatitis C virus (HCV) infection is a global public health issue, which is associated with high rates of morbidity and mortality. The development of direct acting antivirals (DAAs) has transformed treatment: they offer us highly-effective th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c155618ebdf5373a61a82203f443ebb9
https://pubmed.ncbi.nlm.nih.gov/31502544
https://pubmed.ncbi.nlm.nih.gov/31502544
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 160
Pharmaceutical companies are under increasing scrutiny because of their strategy for gaining market access and reimbursement authorisation for novel drugs. The tool most often used is that of a randomised controlled trial (RCT) in a highly selected p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fd18ded4c5afeb9e8d6e89c8881a6f36
https://pubmed.ncbi.nlm.nih.gov/27734779
https://pubmed.ncbi.nlm.nih.gov/27734779
Autor:
Martina, Marzia1 (AUTHOR) marzia.martina@nrc-cnrc.gc.ca, Banderali, Umberto1 (AUTHOR), Yogi, Alvaro1 (AUTHOR), Arbabi Ghahroudi, Mehdi2 (AUTHOR), Liu, Hong1 (AUTHOR), Sulea, Traian3 (AUTHOR), Durocher, Yves3 (AUTHOR), Hussack, Greg2 (AUTHOR), van Faassen, Henk2 (AUTHOR), Chakravarty, Balu1 (AUTHOR), Liu, Qing Yan1 (AUTHOR), Iqbal, Umar1 (AUTHOR), Ling, Binbing1 (AUTHOR), Lessard, Etienne3 (AUTHOR), Sheff, Joey2 (AUTHOR), Robotham, Anna2 (AUTHOR), Callaghan, Debbie2 (AUTHOR), Moreno, Maria1 (AUTHOR), Comas, Tanya1 (AUTHOR), Ly, Dao1 (AUTHOR)
Publikováno v:
Advanced Science. 10/28/2024, Vol. 11 Issue 40, p1-22. 22p.
Publikováno v:
Journal of Viral Hepatitis, 22, 12, pp. 965-73
Journal of Viral Hepatitis, 22, 965-73
Journal of Viral Hepatitis, 22, 965-73
Item does not contain fulltext Hepatitis E viral infection can lead to a chronic infection in immunocompromised patients, resulting in progressive liver disease and cirrhosis. Isolated cases have shown that treatment with ribavirin or pegylated inter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c02ea63381832c8b83a62ac7685f65fd
https://hdl.handle.net/2066/152761
https://hdl.handle.net/2066/152761
Autor:
Drenth JPH; Amsterdam University Medical Center, Amsterdam, the Netherlands.
Publikováno v:
United European gastroenterology journal [United European Gastroenterol J] 2024 Dec; Vol. 12 (10), pp. 1340-1341. Date of Electronic Publication: 2024 Nov 30.
Autor:
M H, Lamers, M M T J, Broekman, C A, Boucher, J T, Brouwer, D M, Burger, B, van Hoek, A I M, Hoepelman, R J, de Knegt, H W, Reesink, J P H, Drenth
Publikováno v:
The Netherlands journal of medicine. 71(7)
In this new Dutch guideline for hepatitis C virus infection we provide recommendations for the management of hepatitis C infection. Until 2012 the standard for treatment consisted of pegylated interferon alpha (peg-IFNa) and ribavirin. The advent of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ab29f4859ca684277940b311600ff9e9
https://pubmed.ncbi.nlm.nih.gov/24038567
https://pubmed.ncbi.nlm.nih.gov/24038567